Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Kína1. fázis

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases

A legfontosabb adatok

Ki végzi
Institute of Hematology & Blood Diseases Hospital, China
Hol
Tianjin (Kína)A helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
1. fázis
Résztvevők
12 fő, tervezett
Kezdés
2025. febr. 11.
Várható befejezés
2028. márc. 18.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • UCAR T-cell
A regiszteradat frissítve
2025. szeptember 29.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

A vizsgálat olyan felnőtteket keres, akiknek nehezen kezelhető autoimmun betegségük kiújult, vagy nem reagált a szokásos kezelésre. A betegségek: lupusz, szisztémás szklerózis, gyulladásos izombetegség, ANCA-asszociált vaszkulitisz, vagy kötőszöveti betegséghez társuló alacsony vérlemezkeszám.

Életkor
18 éves vagy idősebb
Nem
Minden nem részt vehet.
A betegség stádiuma
A betegségnek kiújultnak vagy kezelésre nem reagálónak kell lennie: több mint 6 hónapnyi szokásos kezelésre sem javult, vagy a javulás után kiújult. Minden betegségnél vannak saját aktivitási követelmények is, például lupusznál SLEDAI-2000 legalább 8, ANCA-asszociált vaszkulitisznél BVAS legalább 15.
Korábbi kezelés
Előzőleg ki kellett próbálni a szokásos kezelést: glükokortikoidot és egy vagy több immunszuppresszív gyógyszert vagy biológiai szert (például rituximab, belimumab, tocilizumab). A vizsgálat szövege szerint ez a "hagyományos kezelés".
Biomarker vagy leletérték
A vérben a B-sejteken CD19 vagy BCMA jelenlétét kell kimutatni áramlási citometriával. Egyes betegségeknél pozitív ellenanyagok is kellenek (szklerodermával kapcsolatos ellenanyagok, illetve MPO-ANCA vagy PR3-ANCA).

A részvétel fő kizáró okai

  • Nem kontrollált fertőzés, vagy kezelést igénylő fertőzés
  • Pozitív teszt hepatitis B-re, hepatitis C-re, HIV-re vagy szifilisz-re
  • Daganatos betegség az elmúlt öt évben
  • Várandós nők, vagy akik teherbe esést terveznek
  • Az elmúlt 3 hónapban részt vett másik klinikai vizsgálatban

A regiszter feltételei, szó szerint

Mind a 40 feltétel megnézéseKevesebb

Ki vehet részt

  • Common Inclusion Criteria:
  • Age ≥ 18 years old (inclusive), regardless of gender
  • Positive expression of CD19 or BCMA on peripheral blood B cells confirmed by flow cytometry
  • Functional requirements for major organs are as follows(Except for abnormalities related to autoimmune disease activity): 1) Bone marrow function must meet: A. Neutrophil count ≥ 1×109/L (no colony-stimulating factor treatment within 2 weeks before examination); B. Hemoglobin ≥ 60g/L; 2) Liver function: Alanine aminotransferase (ALT) ≤ 3×ULN (excluding ALT elevation due to inflammatory myopathy), aspartate aminotransferase (AST)≤3×Upper limit of normal (ULN) (excluding AST elevation due to inflammatory myopathy), TBIL≤2×ULN (or ≤ 3.0×ULN for subjects with Gilbert syndrome); 3) Renal function: creatinine clearance rate (CrCl) ≥ 30ml/minute (calculated by Cockcroft/Gault formula, acute CrCl decrease due to the target disease is excluded; LN is exluded)
  • ECOG score 0-2
  • Female subjects of childbearing potential and male subjects with partners of childbearing potential must use medically approved contraception or abstinence during the study treatment period and for at least 6 months after the end of the study treatment; Female subjects of childbearing potential must have a negative Human chorionic gonadotropin (HCG) test within 7 days before study enrollment and not be lactating
  • Willing to participate in this clinical study, sign an informed consent form, have good compliance, and cooperate with follow-up; Disease-Specific Inclusion Criteria; Refractory/Relapsed Systemic Lupus Erythematosus:
  • SLE meeting the 2019 the American College of Rheumatology (ACR) /European League Against Rheumatism (EULAR) and classification criteria
  • Disease activity score SLEDAI-2000 ≥ 8; or with significant organ involvement, such as lupus nephritis (histologically confirmed active nephritis of class III or IV, with or without class V, with an NIH activity index > 2, evidence of increased chronicity index; urine protein-to-creatinine ratio > 1.0 g/g, or 24-hour urinary protein > 1.0 g)
  • Definition of refractory or relapsing disease: lack of response after more than 6 months of conventional therapy, or recurrence of disease activity after remission. Conventional therapy is defined as treatment with glucocorticoids in combination with one or more of the following immunomodulatory agents: cyclophosphamide, antimalarial drugs, azathioprine, mycophenolate mofetil, methotrexate, leflunomide, tacrolimus, cyclosporine, as well as biologics such as rituximab, belimumab, and telitacicept; Refractory/Relapsed/Progressive Systemic Sclerosis:
  • Scleroderma fulfilling the 2013 ACR classification criteria
  • Positive scleroderma-related antibodies
  • Presence of diffuse cutaneous sclerosis or active interstitial lung disease (high-resolution computed tomography (HRCT) showing ground-glass opacities)
  • Definition of relapsed/refractory: Conventional treatment over 6 months remains ineffective, or disease recurrence after remission. Definition of conventional treatment: the use of glucocorticoids , and any one or more of the following immunomodulatory drugs: cyclophosphamide, antimalarials, azathioprine, mycophenolate mofetil, methotrexate, leflunomide, tacrolimus, cyclosporine, and biologics including belimumab, rituximab, and tocilizumab, etc
  • Definition of progressive: Rapid skin progression (mRSS increase > 25%); or progression of lung disease (forced vital capacity (FVC) decrease by 10%, or FVC decrease by more than 5% with diffusing capacity of the lung for carbon monoxide (DLCO) decrease by 15%); Note: Meeting either criterion 4 or 5 is sufficient; Refractory/Relapsed/Progressive Inflammatory Myopathy:
  • Inflammatory myopathy fulfilling the 2017 EULAR/ACR classification criteria (including Dermatomyositis (DM), Polymyositis (PM), Anti-Synthetase Syndrome (ASS), and Necrotizing Myopathy (NM))
  • Muscle involvement with Manual Muscle Testing-8 (MMT-8) score less than 142 and at least two abnormalities found among the following five core measurements (Physician Global Assessment (PhGA), Patient Global Assessment (PtGA), or extramuscular disease activity score ≥ 2; Health Assessment Questionnaire (HAQ) total score ≥ 0.25; muscle enzyme levels ≥ 1.5×ULN)
  • Definition of relapsed/refractory: Conventional treatment over 6 months remains ineffective, or disease recurrence after remission. Definition of conventional treatment: the use of glucocorticoids , and any one or more of the following immunomodulatory drugs: cyclophosphamide, antimalarials, azathioprine, mycophenolate mofetil, methotrexate, leflunomide, tacrolimus, cyclosporine, and biologics including belimumab, rituximab, and tocilizumab, etc
  • Definition of progressive: Rapid progression of interstitial lung disease within a short period; Note: Meeting either criterion 4 or 5 is sufficient; Refractory/Relapsed ANCA-Associated Vasculitis:
  • ANCA-Associated Vasculitis fulfilling 2022 ACR/EULAR criteria, including microscopic polyangiitis, granulomatosis with polyangiitis, and eosinophilic granulomatosis with polyangiitis
  • Positive ANCA-associated antibodies (MPO-ANCA or PR3-ANCA positive)
  • The Birmingham Vasculitis Activity Scale (BVAS) ≥ 15 points (a total score of 63 points), indicating active vasculitis
  • Definition of refractory/relapsed: Conventional treatment over 6 months remains ineffective, or disease recurrence after remission., or disease recurrence after remission. Definition of conventional treatment: the use of glucocorticoids and any one or more of the following immunomodulatory drugs: cyclophosphamide, antimalarials, azathioprine, mycophenolate mofetil, methotrexate, leflunomide, tacrolimus, cyclosporine, and biologics including belimumab, rituximab, and tocilizumab, etc; Refractory/Relapsed Connective Tissue Disease-associated thrombocytopenia
  • Diagnosis of connective tissue disease established according to the latest classification criteria, including but not limited to systemic lupus erythematosus, primary Sjögren's syndrome, antiphospholipid syndrome, and undifferentiated connective tissue disease
  • Confirmed diagnosis of connective tissue disease-associated thrombocytopenia, with platelet count <30 × 10\^9/L, or <50 × 10\^9/L accompanied by a bleeding tendency
  • Bone marrow morphology consistent with immune thrombocytopenia
  • Prior treatment with at least one course of corticosteroid pulse therapy, or high-dose corticosteroids in combination with one or more immunosuppressants (including biologics) for at least 3 months, without achieving partial remission, or inability to maintain efficacy during steroid tapering

Ki nem vehet részt

  • Subjects who have participated in other clinical trials within the past 3 months prior to enrollment
  • Subjects who have received immunosuppressive agents or biologics with therapeutic effects for indications within 5 half-life prior to enrollment
  • Subjects with a history of severe drug allergies or allergic tendencies
  • Presence or suspicion of uncontrolled or treatment-required fungal, bacterial, viral, or other infections
  • Subjects with central nervous system diseases caused by autoimmune diseases or non-autoimmune diseases (including epilepsy, psychosis, organic brain syndrome, cerebral vascular accidents, encephalitis, central nervous system vasculitis)
  • Subjects with insufficient cardiac function
  • History of malignancy within five years
  • Subjects with end-stage renal failure(LN is excluded)
  • Subjects with psychiatric disorders and severe cognitive impairments
  • Subjects who are positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with peripheral blood HBV DNA >ULN; subjects positive for hepatitis C virus (HCV) antibody and peripheral blood HCV RNA; individuals positive for human immunodeficiency virus (HIV) antibody; individuals positive for syphilis testing
  • Subjects with congenital immunoglobulin deficiencies
  • Pregnant women or women planning to conceive
  • Subjects whom the investigator believes have other reasons that make them unsuitable for inclusion in this study

Helyszínek itt: Kína

  • Institute of Hematology & Blood Diseases HospitalTianjin, KínaContact: Ying Wang, PhDRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases

A vizsgálat csoportja

  • UCAR T-cell groupA vizsgált kezelés

    Universal allogeneic anti-CD19/BCMA CAR T-cells. Biological/Vaccine: universal allogeneic anti-CD19/BCM

    Kezelés: UCAR T-cell

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 12.
A regiszteradat frissítve
2025. szeptember 29.